Study
A geroprotective probiotic and its functional metabolite counteract inflammaging to extend healthspan
Aging-associated loss of Bifidobacterium pseudocatenulatum and its metabolite 5-AVAB tracked with inflammaging; supplementation improved healthspan measures in aged mice, not humans.
Summary Can this probiotic or its chemical help people age more healthily? Show / hide ↓
Researchers compared gut bacteria and bacterial chemicals in several groups of Chinese adults, but did not test a treatment in them. They found that Bifidobacterium pseudocatenulatum, a type of gut bacterium, and 5-AVAB, a chemical made by bacteria, were less common with older age. They then gave the bacterium or 5-AVAB to naturally aged mice. The mice showed less inflammaging, meaning the long-lasting inflammation that often increases with age, along with better movement, thinking, and other health measures. These results came from mice, so they do not directly show that the treatment works or is safe for humans.
What this means for you: This is not a reason to buy a probiotic or 5-AVAB supplement. It is an early finding that suggests a possible treatment pathway, but human benefits, doses, and safety remain unknown.
early evidenceXiaoyong Lu and colleagues profiled gut microbiome remodeling across multiple Chinese cohorts and built a microbiome-based aging clock called MicroAge. Bifidobacterium pseudocatenulatum declined with age in both sexes. The team then gave the bacterium orally to naturally aged mice. Treatment improved intestinal homeostasis, reduced inflammatory signals across organs, and improved cognitive-motor performance. It also extended healthspan in the mouse experiments. The proposed active metabolite was 5-aminovaleric acid betaine, or 5-AVAB. Its levels declined with age in human samples. Giving 5-AVAB to aged mice reproduced part of the bacterial treatment effect, including better cognitive and motor performance and lower multiorgan inflammation. The human component is observational. The intervention data are preclinical. The paper does not show that a probiotic or 5-AVAB extends human lifespan, nor does it establish a safe human dose. The results support a testable microbiome-metabolite pathway rather than a clinical recommendation.
Our findings identify the B. pseudocatenulatum-5-AVAB axis as a promising target for microbiome-based interventions to promote healthy aging.
Human microbiome findings are associative. Efficacy and healthspan extension were tested in naturally aged mice, not people. Translation requires controlled human trials, standardized strains or metabolite preparations, and safety data.